Replies to post #9572 on Organovo Holdings, Inc. (ONVO)

[WHP03]

Purchased more stock and more call options (Jan $5 and Feb $4) today. Yes, the overall market is very volatile, and that is putting pressure on ONVO's valuation/share price, but in my view given the guidance is from $1.5MM to $4-6MM in revenue, without heavy influence from the now available kidney services - I am definitely betting that come Jan-Feb we will be no worse off than high $4 range to low $5. If that happens I will be very happy indeed. We already ran up to the high $4 range in the past 30+ days. I can't see how we don't revisit those highs in the next 3-4 months given what's going on with revenue generation and the flow of news we're seeing. Gotta have courage and faith to win, especially when the market is doing what it's doing. For me it's a buying opportunity.

[RandolRocketman]

Don't forget, Organovo has always intended to 3D bio print human tissues for transplant. They have only veered off to the testing samples arena to pay the bills, and avoid having to sell more shares. The care with which they treat they're stock holders should be an example to other biotech companies out there.